comparemela.com

Latest Breaking News On - Vor biopharma - Page 9 : comparemela.com

VCAR33ALLO by Vor BioPharma for Refractory Acute Myeloid Leukemia: Likelihood of Approval

VCAR33ALLO is under clinical development by Vor BioPharma and currently in Phase II for Refractory Acute Myeloid Leukemia.

Vor Bio to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it.

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Vor Biopharma : Bio Corporate Presentation November 2023 -November 02, 2023 at 09:15 am EDT

Vor Biopharma : Bio Corporate Presentation November 2023 -November 02, 2023 at 09:15 am EDT
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Vor Biopharma Inc (NYSE:VOR) Receives $15 19 Average Target Price from Brokerages

Shares of Vor Biopharma Inc. (NYSE:VOR – Get Free Report) have been assigned an average recommendation of “Buy” from the eight brokerages that are presently covering the company, Marketbeat Ratings reports. Eight research analysts have rated the stock with a buy rating. The average 12 month price target among analysts that have issued ratings on […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.